U. Nitz

TL;DR: One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer.

TL;DR: Triple-negative breast cancer is defined by a lack of expression of both estrogen and progesterone receptor as well as human epidermal growth factor receptor 2, characterized by distinct molecular, histological and clinical features including a particularly unfavorable prognosis despite increased sensitivity to standard cytotoxic chemotherapy regimens.

TL;DR: T-DM1 is particularly effective in eliciting antitumor immunity in patients with early breast cancer and in a HER2-expressing orthotopic tumor model, and it is shown that it can be used in combination therapy.

TL;DR: Tandem HD improves both EFS and OS in HRBC, and this therapy effect may be partly attributable to superior efficacy in the subgroup of triple-negative tumors and/or G3 with their poor prognostic marker profile.

TL;DR: In this article, an interim analysis after 15 months' accrual of the prospectively randomized German Arbeitsgemeinschaft Gynakologische Onkologie (AGO) study is presented.